| AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. The NanoTab System has successfully completed two of its three planned Phase 3 clinical trials and a New Drug Application submission is planned for the third quarter of 2013. AcelRx recently completed enrollment in a Phase 2 study for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC, and top-line results are expected in the second quarter of 2013. The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. . | | |
 |
| 05/29/13 | AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare| REDWOOD CITY, Calif., May 29, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt, New York in New York, NY. The presentation is scheduled for Tuesday, June 4, 2013 at 1... |
|  | | 05/21/13 | Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain| - Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p<0.001) -
- Results confirm all previously reported Phase 3 trial outcomes, supporting submission of an NDA anticipated for third quarter 2013 -
- AcelRx to conduct conference call and webcast today, May 21, 8:30 a.m. EDT (5:30 a.m. PDT) -
REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc... |
| | | 05/16/13 | AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference| REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York, NY. The presentation is scheduled for Wednesday, May 22, 2013 at 9:30 a.m... |
| |
|
|
| Date | Title | 06/27/13 9:00 a.m.
through
06/27/13 11:00 a.m. ET | |
|
Receive E-mail Alerts  | Sign up to receive e-mail alerts whenever AcelRx Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
Print Page | 
E-mail Page | 
RSS Feeds